OPB 51602

Drug Profile

OPB 51602

Alternative Names: OPB-51602

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Multiple myeloma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 18 Jun 2015 National University Hospital in collaboration with Otsuka and Shin Nippon terminates a phase I trial in Nasopharyngeal cancer (Late-stage disease) in Singapore (NCT02058017)
  • 01 Apr 2014 Otsuka Pharmaceutical completes a phase I trial in Multiple myeloma, Non-Hodgkin lymphoma, Acute myeloid leukaemia, Acute lymphoid leukaemia, Chronic myeloid leukaemia (Second-line therapy or greater) in Japan (NCT01344876)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top